<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ABSTRACTBackground: This review examines the associations between low <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> levels, <z:hpo ids='HP_0002180'>neurodegenerative disease</z:hpo>, and <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The potential impact of comorbidities and medications associated with <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> derangements were also investigated </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, we reviewed the evidence as to whether <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> therapy is efficacious for <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> and <z:hpo ids='HP_0000726'>dementia</z:hpo>.Methods: A systematic literature search identified 43 studies investigating the association of <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> and <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> or <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Seventeen studies reported on the efficacy of <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> therapy for these conditions.Results: <z:chebi fb="9" ids="17439">Vitamin B12</z:chebi> levels in the subclinical low-<z:mpath ids='MPATH_458'>normal</z:mpath> range (&lt;250 ρmol/L) are associated with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, and <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Vegetarianism and <z:chebi fb="0" ids="6801">metformin</z:chebi> use contribute to depressed <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> levels and may independently increase the risk for <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0100502'>Vitamin B12 deficiency</z:hpo> (&lt;150 ρmol/L) is associated with <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="9" ids="17439">Vitamin B12</z:chebi> supplements administered orally or parenterally at high dose (1 mg daily) were effective in correcting biochemical deficiency, but improved cognition only in patients with pre-existing <z:hpo ids='HP_0100502'>vitamin B12 deficiency</z:hpo> (serum <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> levels &lt;150 ρmol/L or serum <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels &gt;19.9 μmol/L).Conclusion: Low serum <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> levels are associated with <z:hpo ids='HP_0002180'>neurodegenerative disease</z:hpo> and <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>There is a small subset of <z:hpo ids='HP_0000726'>dementias</z:hpo> that are reversible with <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> therapy and this treatment is inexpensive and safe </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="9" ids="17439">Vitamin B12</z:chebi> therapy does not improve cognition in patients without pre-existing deficiency </plain></SENT>
<SENT sid="9" pm="."><plain>There is a need for large, well-resourced clinical trials to close the gaps in our current understanding of the nature of the associations of <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> insufficiency and <z:hpo ids='HP_0002180'>neurodegenerative disease</z:hpo> </plain></SENT>
</text></document>